AT17300U3 - Feste orale pharmazeutische Zusammensetzung - Google Patents

Feste orale pharmazeutische Zusammensetzung Download PDF

Info

Publication number
AT17300U3
AT17300U3 ATGM113/2020U AT1132020U AT17300U3 AT 17300 U3 AT17300 U3 AT 17300U3 AT 1132020 U AT1132020 U AT 1132020U AT 17300 U3 AT17300 U3 AT 17300U3
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
solid oral
oral pharmaceutical
disintegrant
lubricant
Prior art date
Application number
ATGM113/2020U
Other languages
English (en)
Other versions
AT17300U2 (de
Original Assignee
G L Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G L Pharma Gmbh filed Critical G L Pharma Gmbh
Priority to ATGM113/2020U priority Critical patent/AT17300U3/de
Publication of AT17300U2 publication Critical patent/AT17300U2/de
Publication of AT17300U3 publication Critical patent/AT17300U3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Feste orale pharmazeutische Zusammensetzung enthaltend Lurasidon oder ein pharmazeutisch annehmbares Salz davon, Stärke, Zuckeralkohol, ein Sprengmittel, und ein Schmiermittel.
ATGM113/2020U 2020-12-03 2020-12-03 Feste orale pharmazeutische Zusammensetzung AT17300U3 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ATGM113/2020U AT17300U3 (de) 2020-12-03 2020-12-03 Feste orale pharmazeutische Zusammensetzung

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ATGM113/2020U AT17300U3 (de) 2020-12-03 2020-12-03 Feste orale pharmazeutische Zusammensetzung

Publications (2)

Publication Number Publication Date
AT17300U2 AT17300U2 (de) 2021-12-15
AT17300U3 true AT17300U3 (de) 2022-02-15

Family

ID=78951103

Family Applications (1)

Application Number Title Priority Date Filing Date
ATGM113/2020U AT17300U3 (de) 2020-12-03 2020-12-03 Feste orale pharmazeutische Zusammensetzung

Country Status (1)

Country Link
AT (1) AT17300U3 (de)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1884242A1 (de) * 2005-05-26 2008-02-06 Dainippon Sumitomo Pharma Co., Ltd. Pharmazeutische zusammensetzung
EP1974724A2 (de) * 2000-09-22 2008-10-01 Dainippon Sumitomo Pharma Co., Ltd. Orale Zubereitungen mit guten Zerfallseigenschaften
CN103054824A (zh) * 2012-12-21 2013-04-24 北京万全德众医药生物技术有限公司 盐酸鲁拉西酮口崩片制剂及其制备方法
WO2016139683A2 (en) * 2015-03-05 2016-09-09 Jubilant Generics Limited Pharmaceutical compositions of lurasidone and process for preparing the same
CN106074414A (zh) * 2012-07-12 2016-11-09 成都康弘药业集团股份有限公司 一种含有鲁拉西酮的口腔崩解片及其制备方法
CN106539768A (zh) * 2015-09-18 2017-03-29 成都康弘药业集团股份有限公司 一种盐酸鲁拉西酮口腔崩解片及其制备方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1974724A2 (de) * 2000-09-22 2008-10-01 Dainippon Sumitomo Pharma Co., Ltd. Orale Zubereitungen mit guten Zerfallseigenschaften
EP1884242A1 (de) * 2005-05-26 2008-02-06 Dainippon Sumitomo Pharma Co., Ltd. Pharmazeutische zusammensetzung
CN106074414A (zh) * 2012-07-12 2016-11-09 成都康弘药业集团股份有限公司 一种含有鲁拉西酮的口腔崩解片及其制备方法
CN103054824A (zh) * 2012-12-21 2013-04-24 北京万全德众医药生物技术有限公司 盐酸鲁拉西酮口崩片制剂及其制备方法
WO2016139683A2 (en) * 2015-03-05 2016-09-09 Jubilant Generics Limited Pharmaceutical compositions of lurasidone and process for preparing the same
CN106539768A (zh) * 2015-09-18 2017-03-29 成都康弘药业集团股份有限公司 一种盐酸鲁拉西酮口腔崩解片及其制备方法

Also Published As

Publication number Publication date
AT17300U2 (de) 2021-12-15

Similar Documents

Publication Publication Date Title
AU2018335259A1 (en) High dosage valbenazine formulation and compositions, methods, and kits related thereto
ES2579857T3 (es) Composiciones de plasma rico en plaquetas
PE20110121A1 (es) Composiciones farmaceuticas de aliskiren
IL168266A (en) Nucleoside derivatives, processes for their preparation. pharmaceutical compositions comprising them and uses thereof for the manufacture of medicaments
BR0207726A (pt) Sais farmacêuticos
AR069031A1 (es) Composicion
UY27549A1 (es) Composiciones farmacéuticas para el tratamiento de la diabetes mellitus de tipo ii
NO20081038L (no) Farmasoytiske formuleringer/sammensetninger av guanfacin egnet for daglig enkel doseform administrering
NZ590184A (en) Solid forms of (2s,3r,4r,5s,6r)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2h-pyran-3,4,5-triol and methods of their use
TR200201174T2 (tr) Florokinolon antibiyotik ilacı ve iksantan zamkı içeren farmasötik bileşimler.
EP4667003A3 (de) Zweischichtige pharmazeutische tablettenformulierung
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
PH12022552454A1 (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or pharmaceutically acceptable salt, hydrate, or solvate thereof
CO6150126A2 (es) Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina
EP4110301A4 (de) Pharmazeutische zusammensetzung zur oralen verabreichung
PH12022550937A1 (en) Pharmaceutical composition comprising selexipag
NO20090262L (no) Galeniske formuleringer av aliskiren og hydroklorotiazid
HUP0300378A2 (hu) Oxazolidinontartalmú tablettakészítmények és előállításuk
JP2019522030A5 (de)
MX2021010338A (es) Composicion farmaceutica que contiene acetominofeno e ibuprofeno.
ECSP066872A (es) Tabletas desintegrantes que comprenden licarbazepina
ATE474558T1 (de) Pharmazeutische formulierungen mit irbesartan
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung
ATE465741T1 (de) 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl- y-aminopropyl-azalide mit antimalaria-aktivität